Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes

Drug Metabolism and Disposition

Volumn 33, Issue 1, 2005, Pages 121-130

  Xu, Shiyao ^a   Zhu, Bing ^a   Teffera, Yohannes ^a,b   Pan, Deborah E ^a   Caldwell, Charles G ^a   Doss, George ^a   Stearns, Ralph A ^a   Evans, David C ^a   Beconi, Maria G ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b AMGEN INC   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [[(2,4 DIFLUOROPHENYL)SULFONYL]AMINO]CYCLOHEXYL] 2 (3 FLUOROPYRROLIDIN 1 YL) 2 OXOETHANAMINIUM CHLORIDE; 1 [4 [[(4 TRIFLUOROMETHOXYPHENYL)SULFONYL]AMINO]CYCLOHEXYL] 2 (3 FLUOROPYRROLIDIN 1 YL) 2 OXOETHANAMINIUM CHLORIDE; 16ALPHA CYANOPREGNENOLONE; ACETYLCYSTEINE; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXAMETHASONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; GLUTATHIONE; LIVER PROTEIN; PYRROLIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEMICARBAZIDE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEFLUORINATION; LIVER MICROSOME; MALE; MASS SPECTROMETRY; METABOLIC ACTIVATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIGENS, CD26; BIOTRANSFORMATION; FLUORINE; MALE; MICROSOMES, LIVER; PROTEASE INHIBITORS; PROTEIN BINDING; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 11144285534     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001842     Document Type: Article

References (22)

1. Ahren B, Simonsson E, and Larsson H (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875.
2. Augustyns KJL, Lambeir AM, Borloo M, De Meester I, Vedernikova I, Vanhoof G, Hendriks D, Scharpé S, and Haemers A (1997) Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. Eur J Med Chem 32:301-309.
3. Baillie TA and Davis MR (1993) Mass speccrometry in the analysis of glutathione conjugates. Biol Mass Spectrum 22:319-325.
4. Baillie TA and Kassahun K (2001) Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Adv Exp Med Biol 500:45-51.
5. Caldwell CG, Chen P, He J, Parmee ER, Leiting B, Marsilio F, Patel RA, Wu JK, Eiermann GJ, Petrov A, et al. (2004) Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 14:1265-1268.
6. Drucker DJ (2003) Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 12:87-100.
7. Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16.
8. Fournel S, Magdalou J, Batt AM, and Siest G (1983) Comparative study of four hypolipidaemic agents on the activity of drug-metabolizing enzymes in rat liver microsomes. Int J Clin Pharmacol Res 3:431-436.
9. Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, and McIntosh CHS (2002) Dipeptidyl peptidase IV - resistant glucose-dependent insulinotropic polypeptide improves glucose tolerance in normal and obese diabetic rats. Diabetes 51:652-661.
10. Hoffmann T, Glund K, and McIntosh CHS (2001) DPPIV inhibition as treatment of type II diabetes, in Cell-Surface Aminopeptidases: Basic and Clinical Aspects (Mizutani S ed) pp381-387, Elsevier Science Inc., New York.
11. King H, Auber RE, and Herman WH (1998) Global burden of diabetes, 1995-2005: prevalence, numerical estimates and projections. Diabetes Care 21:1414-1431.
12. Loh KC and Leow MK (2002) Current therapeutic strategies for type 2 diabetes mellitus. Ann Acad Med Singapore 31:722-729.
13. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24.
14. Nelson SD and Pearson PG (1990) Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals. Annu Rev Pharmacol Toxicol 30:169-195.
15. Parkinson A (2001) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology: The Basic Scientific of Poisons (Klaassen CD ed), pp 133-124, McGraw-Hill Companies, New York.
16. Raucy JL and Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:557-587.
17. Reimer MK, Holst JJ, and Ahren B (2002) Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727.
18. Riddle MC (2003) Sulfonylureas differ in effects on ischemic preconditioning - is it time to retire glyburide? J Clin Endocrinol Metab 88:528-530.
19. Streeper RT, Pearson PG, Zhao Z, Mizsak SA, Sanders PE, Wienkers LC, and Vrbanac JJ (1997) In vitro metabolic transformations of 2,4- dipyrrolidinylpyrimidine: a chemical probe for P450-mediated oxidation of tirilazad mesylate. Xenobiotica 27:1131-1145.
20. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, and Aubert ML (2002) Chronic inhibition of circulating dipeptidase IV by FE999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51:1461-1469.
21. Tadayyon M and Smith SA (2003) Insulin sensitisation in the treatment of type 2 diabetes. Expert Opin Investig Drugs 12:307-324.
22. Uetrecht JP (1999) New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 12:387-395.